Loading...
WCLC congress 20182025-01-28T16:43:24+01:00

WCLC 2018 – Toronto

Lecture Board: Heidi A. Hamann, PhD; Vera Hirsh, MD; Maximilian Hochmair, MD; Herbert Ho Fung Loong, MD
Medical Writer: Dr. Judith Moser

DOWNLOADS

All downloads from WCLC 2018

WCLC 2018 English

Full report (english)

WCLC 2018 Mandarin

Full report (mandarin)

WCLC 2018 Japanese

Full report (japanese)

EXPERT VIDEOS

All video interviews from WCLC 2018

Herbert Loong on peculiarities of lung cancer research with a focus on phase I studies.

James Ho talks about novel diagnostic approaches, monitoring of lung cancer patients as well as the potential for the use of antioxidants in lung cancer.

Maximilian Hochmair on the future of combinations of immunotherapies with other drugs as well as his recommendations for treatment sequencing in ALK-positive and EGFR-positive lung cancer.

Vera Hirsh discusses the latest clinical achievements using <em>EGFR</em>-targeted therapy in patients with advanced NSCLC and the role of patient quality of life.

This is the first study in more than 20 years to show a clinically meaningful survival improvement over the current first-line standard of care in this setting. A singular survival benefit has also been obtained with durvalumab in unresectable, stage III non–small-cell lung cancer.

Vera Hirsh • MD, Department of Oncology, McGill University Health Center, Montreal, Canada
Go to Top